Preclinical studies demonstrated that the administration of the AT1R antagonist telmisartan for 20 weeks to ApoE−/− mice reduces atherosclerosis progression, with decreased lipid deposition and accumulation of macrophages [82]. Here, AGTR1 is linked to atherosclerosis.